Clinical Trials: Biomarkers to Support Clinical Endpoints

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$695

This report provides a comprehensive analysis of biomarkers in clinical trials. The purpose of this report is to offer valuable insights into the landscape of clinical trials involving biomarkers by highlighting trends and patterns across various dimensions. Ultimately, this report serves as a resource for researchers, clinicians, and industry stakeholders seeking to understand the evolving role of biomarkers in clinical trials. The insights derived from this analysis can inform future research directions, enhance trial design, and contribute to feasibility planning.

This report presents a thorough analysis of biomarkers in clinical trials, aiming to illuminate the evolving landscape of biomarker utilization in research and development. By examining trends and patterns across various dimensions, this report serves as a vital resource for researchers, clinicians, and industry stakeholders who seek to understand the critical role biomarkers play in clinical trials. The insights derived from this comprehensive analysis are intended to inform future research directions, enhance trial design, and contribute to effective feasibility planning. Overall, this report provides critical insights that can guide stakeholders in navigating the complexities of biomarker integration in clinical trials, ultimately fostering innovation and improving patient outcomes in the evolving landscape of medical research.

Scope

The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials with biomarkers captured in the database from May 27–July 11, 2025. The trials were analyzed and segmented by year, endpoint status, duration, phase, single-country versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, intervention, biomarkers, drug type, and DCT use. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Reasons to Buy

In-Depth Analysis: Gain access to a comprehensive analysis of biomarkers in clinical trials, providing valuable insights into current trends, patterns, and the overall landscape of biomarker research.

Data-Driven Insights: Leverage data-driven findings that highlight key metrics, such as trial durations and sponsorship trends, enabling informed decision-making for researchers and industry stakeholders.

Strategic Planning: Utilize the insights from this report to enhance trial design and feasibility planning, ensuring that your research initiatives are aligned with the latest developments in biomarker utilization.

Understanding Market Dynamics: Stay ahead of the curve by understanding the evolving role of biomarkers in clinical trials, including the factors contributing to the decline in biomarker usage since 2021.

Resource for Stakeholders: This report serves as an essential resource for researchers, clinicians, and industry professionals, offering guidance on navigating the complexities of biomarker integration in clinical trials.

Future Research Directions: Identify potential areas for future research and development, helping to shape your organization’s strategic focus and investment in biomarker-related projects.

Competitive Advantage: Equip your organization with the knowledge needed to maintain a competitive edge in the rapidly evolving field of biomarker research and clinical trials.

Networking Opportunities: By understanding the landscape of non-industry sponsored trials, stakeholders can identify potential collaborators and partnerships within the academic and independent research communities.

Regulatory Insights: Gain insights into regulatory considerations and challenges associated with biomarker trials, helping to navigate compliance and approval processes more effectively.

Comprehensive Resource: This report consolidates a wealth of information into a single resource, saving time and effort in research and analysis for busy professionals in the field.

Table of Contents

1.Tables and Figures

2.Executive Summary

3.Introduction

4.Clinical Trials: Biomarkers to Support Clinical Endpoints

5.Key Findings

6.Appendix

Figures

Figure 1: Proportion of total trials with and without biomarkers, by year

Figure 2: Number of biomarker trials and artificial intelligence trials, by year

Figure 3: Clinical trial cost estimates for trials with biomarkers and all trials, by phase

Figure 4: Percentage of trials with biomarkers used to assess efficacy and safety

Figure 5: Trials with or without biomarkers, by endpoint status

Figure 6: Percentage of trials with or without biomarkers, by region

Figure 7: Percentage of trials with biomarkers used to assess safety or efficacy, by region

Figure 8: Comparing ratio of multinational trials/single country trials in all trials and trials with biomarkers, by region

Figure 9: Trials with biomarkers used to assess safety or efficacy endpoints, by trial phase

Figure 10: Percentage of trials with and without biomarkers, by trial status

Figure 11: Percentage of trials with biomarkers used to assess safety or efficacy, by trial status

Figure 12: Total decentralized/virtual trials with or without biomarkers, by decentralized/virtual component

Figure 13: Percentage of biomarkers trials with virtual components, by endpoint classification

Figure 14: Diversity in trials with and without biomarkers

Figure 15: Duration of trials with and without biomarkers

Figure 16: Duration of trials utilizing biomarkers, by endpoint classification

Figure 17: Comparing all trials and trials with biomarkers, by molecule type

Figure 18 and 19: Top 10 therapy areas investigated in trials with biomarkers assessing safety or efficacy endpoints

Figure 20 and 21: Top 10 drugs investigated in trials using biomarkers to support safety or efficacy endpoints

Figure 22: Top 10 efficacy biomarkers supporting efficacy clinical endpoints

Figure 23: Top 10 safety biomarkers supporting safety clinical endpoints

Figure 24 and 25: Trials with biomarkers assessing safety or efficacy endpoints, by sponsor type

Figure 26 and 27: Trials with biomarkers assessing safety or efficacy endpoints, by sponsor type

Figure 28 and 29: Top 10 Industry sponsors in trials with biomarkers, by endpoint classification

Figure 30 and 31: Top 10 non-Industry sponsors in trials with biomarkers, by endpoint classification

Figure 32: Rare disease clinical trials with or without biomarkers and AI trials, by year

Figure 33 and 34: Rare disease trials using biomarkers to assess safety and efficacy endpoints, by endpoint status

Clinical Trials: Biomarkers to Support Clinical Endpoints standard reports
Currency USD
$695

Can be used by individual purchaser only

$1,390

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clinical Trials: Biomarkers to Support Clinical Endpoints in real time.

  • Access a live Clinical Trials: Biomarkers to Support Clinical Endpoints dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.